The next meeting of the National Drug Scheduling Advisory Committee (NDSAC) is scheduled for June 1, 2025. The primary purpose of the meeting is to consider the following matter:

• Request for Schedule III status for esomeprazole magnesium trihydrate delayed release capsules, for human use, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in multi-treatment course packages containing two (package size of 560 mg) or three (package size of 840 mg) courses of treatment.

Interested Party

Individuals, companies or organizations seeking Interested Party status for this agenda item are invited to complete the Interested Party Application Form and submit it to NAPRA as soon as possible. All applications for Interested Party status must be submitted in writing to the NDSAC Secretariat via email no later than 4:00 p.m. (ET) on Thursday, April 17, 2025.

Alternate Method of Participation

Individuals, companies or organizations who chose not to pursue Interested Party status or have been denied the status can provide comments, in writing, related to the agenda item outlined above. The comments must be received by the NDSAC Secretariat via email no later than 4:00 p.m. (ET) on Friday, May 23, 2025. Please note: only an acknowledgement of receipt for the comments received will be provided. All comments or information provided by this alternate method of participation shall be provided to NAPRA and any person, association or other entity that has obtained Interested Party status.

For more information, please contact the NDSAC Secretariat via email at ndsac@napra.ca.